Best Practice & Research Clinical Haematology
Volume 20, Issue 2 , Pages 171-187 , June 2007

Risk assessment in haematopoietic stem cell transplantation: Minor histocompatibility antigens

References 

  1. Goulmy E. Human minor histocompatibility antigens. Current Opinion in Immunology. 1996;8(75):81
  2. Goulmy E, Termijtelen A, Bradley B, et al. Y-antigen killing by T cells of women is restricted by HLA. Nature. 1977;266:544–545
  3. Goulmy E, Termijtelen A, Bradley B, et al. Alloimmunity to human H-Y. Lancet. 1976;308(7996):1206
  4. Voogt P, Fibbe W, Marijt WA, et al. Rejection of bone marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens. Lancet. 1990;335:131–134
  5. Horowitz M, Gale R, Sondel P, et al. Graft-verus-leukemia reactions after bone-marrow transplantation. Blood. 1990;75:555–562
  6. Kolb H, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76(12):2462–2465
  7. Atkinson K, Farrell C, Chapman G, et al. Female marrow donors increase the risk of acute graft-versus-host disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum. British Journal of Haematology. 1986;63(2):231–239
  8. Gratwohl A, Hermans J, Niederwieser D, et al. Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. The Hematology Journal. 2001;2(6):363–370
  9. Randolph SS, Gooley TA, Warren EH, et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood. 2004;103(1):347–352
  10. Takami A, Sugimori C, Feng X, et al. Expansion and activation of minor histocompatibility antigen HY-specific T cells associated with graft-versus-leukemia response. Bone Marrow Transplantation. 2004;34(8):703–709
  11. Gahrton G, Iacobelli S, Apperley J, et al. The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplantation. 2005;35(6):609–617
  12. de Bueger M, Bakker A, van Rood J, et al. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicated heterogenity among human cytotoxic T lymphocyte-defined non-MHC antigens. Journal of Immunology. 1992;149(5):1788–1794
  13. Dickinson A, Wang X, Sviland L, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nature Medicine. 2002;8(4):410–414
  14. van Lochem E, van der Keur M, Mommaas AM, et al. Functional expression of minor histocompatibility antigens on human peripheral blood dendritic cells and epidermal Langerhans cells. Transplant Immunology. 1996;4(2):151–157
  15. van der Harst D, Goulmy E, Falkenburg J, et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood. 1994;83:1060–1066
  16. Marijt W, Heemskerk M, Kloosterboer F, et al. Hematopoiesis-restricted minor histocompatibilty antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(5):2742–2747
  17. Klein C, Wilke M, Pool J, et al. The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. The Journal of Experimental Medicine. 2002;196(3):359–368
  18. Tykodi S, Warren E, Thompson J, et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clinical Cancer Research. 2004;10(23):7799–7811
  19. Spierings E, Wieles B, Goulmy E. Minor histocompatibility antigens - big in tumour therapy. Trends in Immunology. 2004;25(2):56–60
  20. Akatsuka Y, Nishida T, Kondo E, et al. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic linegae-specific minor histocompatibility antigens. The Journal of Experimental Medicine. 2003;197(11):1489–1500
  21. Shlomchik W, Couzens M, Tang C, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285(5426):412–419
  22. Mapara M, Kim Y, Wang S, et al. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood. 2002;100:1903–1909
  23. Matte C, Liu J, Cormier J, et al. Donor APCs are required for maximal GvHD but not for GvL. Nature Medicine. 2004;10(9):987–992
  24. Collin MP, Hart DN, Jackson GH, et al. The fate of human Langerhans cells in hematopoietic stem cell transplantation. The Journal of Experimental Medicine. 2006;203(1):27–33
  25. Goulmy E, Schnipper R, Pool J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recepients and the development of graft-versus-host disease after bone marrow transplantation. The New England Journal of Medicine. 1996;334:281–285
  26. Tait B, Maddison R, McCluskey J, et al. Clinical relevance of the minor histocompatibility antigen HA-1 in allogeneic bone marrow transplantation between HLA identical siblings. Transplantation Proceedings. 2001;33:1760–1761
  27. Socié G, Loiseau P, Tamouza R, et al. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation. 2001;72(4):699–706
  28. Gallardo D, Arostegui J, Balas A, et al. Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibbling donor transplantation. British Journal of Haematology. 2001;114:931–936
  29. Kolb HJ, Rank A, Chen X, et al. In-vivo generation of leukaemia-derived dendritic cells. Best Practice & Research. Clinical Haematology. 2004;17(3):439–451
  30. Hambach L, Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens. Current Opinion in Immunology. 2005;17:202–210
  31. Kollman C, Howe C, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98(7):2043–2051
  32. Verdijk R, Pool J, van der Keur M, et al. Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. Blood. 2004;103(5):1961–1963
  33. James E, Chai J, Dewchand H, et al. Multiparity induces priming to male-specific minor histocompatibility antigen, HY, in mice and humans. Blood. 2003;102(1):388–393
  34. Mommaas B, Stegehuis-Kamp J, van Halteren A, et al. Cord blood comprises antigen-experienced T cells specific for maternal minor histocompatibility antigen HA-1. Blood. 2004;105(4):1823–1827
  35. Goulmy E, Hamilton J, Bradley B, et al. HLA restricted killing of male targerts by multi-transfused females in the cell mediated lympholysis test. Cell Biology and Immunology of Leucocyte Function. 1979;589–594
  36. den Haan J, Meadows L, Wang W, et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science. 1998;279:1054–1057
  37. Mommaas B, Kamp J, Drijfhout J, et al. Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus. Journal of Immunology. 2003;169(6):3131–3136
  38. Slager EH, Honders MW, van der Meijden ED, et al. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood. 2006;107(12):4954–4960
  39. den Haan J, Sherman N, Blokland E, et al. Identification of a graft versus host disease-associated human mior histocompatibility antigen. Science. 1995;268:1476–1480
  40. Dolstra H, Fredrix H, Maas F, et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. The Journal of Experimental Medicine. 1999;189(2):301–308
  41. Brickner AG, Evans AM, Mito JK, et al. The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood. 2006;107(9):3779–3786
  42. de Rijke B, Horssen-Zoetbrood A, Beekman JM, et al. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. The Journal of Clinical Investigation. 2005;115(12):3506–3516
  43. Mutis T, Verdijk R, Schrama E, et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood. 1999;93:2336–2341
  44. Hambach L, Nijmeijer B, Aghai Z, et al. Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice. Leukemia. 2006;20:371–374
  45. Heemskerk M, Hoogeboom M, de Paus R, et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood. 2003;102(10):3530–3540
  46. Mommaas B, van Halteren AG, Pool J, et al. Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer. Haematologica. 2005;90(10):1415–1421
  47. Minor H antigen database. http://www.lumc.nl/dbminor.
  48. Vogt M, van den Muijsenberg J, Goulmy E, et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood. 2002;99(8):3027–3032
  49. Spierings E, Vermeulen C, Vogt M, et al. Identification of HLA class II-restricted H-Y specific T helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation. Lancet. 2003;362(9384):590–591
  50. Zorn E, Miklos DB, Floyd BH, et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. The Journal of Experimental Medicine. 2004;199(8):1133–1142
  51. Spierings E, Brickner A, Caldwell J, et al. The minor Histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood. 2003;102(2):621–629
  52. de Bueger M, Bakker A, Goulmy E. Acquired tolerance for minor Histocompatibility antigens after HLA identical bone marrow transplantation. International Immunology. 1992;4:53–57
  53. Boeck S, Hamann M, Pihusch V, et al. Kinetics of dendritic cell chimerism and T cell chimerism in allogeneic hematopoietic stem cell recipients. Bone Marrow Transplantation. 2006;37(1):57–64
  54. van Els C, D'Amaro J, Pool J, et al. Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. Immunogenetics. 1992;35:161–165
  55. Kloosterboer FM, Luxemburg-Heijs SA, van Soest RA, et al. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Leukemia. 2004;18(4):798–808
  56. Rufer N, Wolpert E, Helg C, et al. HA-1 and the SMCY-derived peptide fidsyicqv (H-Y) are immunodominant minor Histocompatibility antigens after bone marrow transplantation. Transplantation. 1998;66:910–967
  57. Goulmy E, Blokland E, Fassbinder W, et al. Occurrence of posttransplant donor-specific cell-mediated lympholysis nonreactivity in renal allograft recipients with perioperative transfusions only. Transplantation. 1985;39(1):105–107
  58. Cai J, Lee J, Jankowska-Gan E, et al. Minor H antigen HA-1-specific regulator and effector CD8+ T cells, and HA-1 microchimerism, in allograft tolerance. The Journal of Experimental Medicine. 2004;199(7):1017–1023
  59. Hambach L, Nijmeijer BA, Drabbels JJ, et al. Chromosomal aberrations in leukaemia cells may delete tumour target antigens of stem cell-based immunotherapy. Leukemia. 2006;20(7):1298–1300
  60. Miyazaki M, Akatsuka Y, Nishida T, et al. Potential limitations in using minor histocompatibility antigen-specific cytotoxic T cells for targeting solid tumor cells. Clinical Immunology. 2003;107(3):198–201
  61. Murata M, Warren E, Riddell S. A human minor histocompatibility antigen resutling from differential expression due to a gene deletion. The Journal of Experimental Medicine. 2003;197(10):1279–1289
  62. Warren E, Gavin M, Simpson E, et al. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. Journal of Immunology. 2000;164(5):2807–2814
  63. Ivanov R, Aarts T, Hol S, et al. Identification of a 40S ribosomal protein S4-derived H-Y epitope able to elicit a lymphoblast-specific cytotoxic T lymphocyte response. Clinical Cancer Research. 2005;11(5):1694–1703
  64. Pierce R, Field E, den Haan J, et al. Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cyteine residue as identified by a novel mass spectrometric technique. Journal of Immunology. 1999;163(12):6360–6364
  65. Vogt M, de Paus R, Voogt P, et al. DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood. 2000;95(3):1100–1105
  66. Meadows L, Wang W, den Haan J, et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity. 1997;6(3):273–281
  67. Brickner A, Warren E, Caldwell J, et al. The Immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. The Journal of Experimental Medicine. 2001;193(2):15–205
  68. Torikai H, Akatsuka Y, Miyazaki M, et al. A novel HLA-A*3303-restricted minor histocompatibility antigen encoded by an unconventional open reading frame of human TMSB4Y gene. Journal of Immunology. 2004;173(11):7046–7054
  69. Wang W, Meadows L, den Haan J, et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science. 1995;269(5230):1588–1590
  70. Vogt M, Goulmy E, Kloosterboer F, et al. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood. 2000;96:3126–3132
  71. Spierings E, Drabbels J, Hendriks M et al. Uniform genomic minor histocompatibility antigen typing methodology and database designed to facilitate clinical applications. PLoS One 2006, in press.

PII: S1521-6926(06)00062-4

doi: 10.1016/j.beha.2006.09.002

Best Practice & Research Clinical Haematology
Volume 20, Issue 2 , Pages 171-187 , June 2007

Article Tools

* Image Usage & Resolution